Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis

Abstract

IMPORTANCETumor necrosis factor inhibitors (TNFis) have revolutionized the management of ankylosing spondylitis (AS); however, the lack of notable clinical responses in approximately one-half of patients suggests important heterogeneity in treatment response. Identifying patients likely to respond or not respond to TNFis could provide opportunities to personalize treatment strategies. OBJECTIVE To develop models of the probability of short-term response to TNFi treatment in individual patients with active AS. DESIGN, SETTING, AND PARTICIPANTS This is a retrospective cohort study using data of the TNFi group (ie, treatment group) from 10 randomized clinical trials (RCTs) of TNFi treatment among patients with active AS, conducted from 2002 to 2016. Participants were adult patients with active AS who failed nonsteroidal anti-inflammatory drugs. Included RCTs were phase 3 and 4 studies that assessed the efficacy of an originator TNFi at week 12 and/or week 24, either compared with placebo or an antirheumatic drug. The cohort was divided into a training and a testing set. Data analysis was conducted from July 1, 2019, to November 30, 2020. EXPOSURES All included patients received an originator TNFi for at least 12 weeks. MAIN OUTCOMES AND MEASURES Outcomes included major response and no response based on the change of AS Disease Activity Score at 12 weeks. Machine learning algorithms were applied to estimate the probability of having major response and no response for individual patients. RESULTSThe study included 1899 participants from 10 trials. The training set included 1207 individuals (mean [SD] age, 39 [12] years; 908 [75.2%] men), of whom 407 (33.7%) had major response and 414 (34.3%) had no response. In the reduced logistic regression models, accuracy was 0.74 for major response and 0.75 for no response. The probability of major response increased with higher C-reactive protein (CRP) level, patient global assessment (PGA), and Bath AS Disease Activity Index (BASDAI) question 2 score and decreased with higher body mass index (BMI) and Bath AS Functional Index (BASFI) score. The probability of no response increased with age and BASFI score, and decreased with higher CRP level, BASDAI question 2 score, and PGA. In the testing set (692 participants; mean [SD] age, 38 [11] years; 533 [77.0%] men), models demonstrated moderate to high accuracy. CONCLUSIONS AND RELEVANCEIn this cohort study, the probability of initial response to TNFi was predicted from baseline variables, which may facilitate personalized treatment decision-making.

HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry

“…As all these additional parameters seem differently expressed in the B27+ vs. B27− population, B27− patients might be discriminated a priori, if both genotype and phenotype-related parameters are considered. In a more recent attempt to predict probability of response to TNFi for individual patients using machine learning algorithms, the HLA-B27 genotype ranked relatively low for predicting major response if specific baseline characteristics, including CRP levels, were taken into account [18]. Classification as nonradiographic vs. radiographic axSpA had no significant impact on TNFi retention or response in our analysis, confirming data from another cohort [19].…”

Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment

“…Nevertheless, it may mitigate overfitting problems compared with the 1-stage modeling approach . Moreover, because the stage 1 risk model can be replaced by alternative models, future studies with ample sample sizes can explore advanced machine learning methods . In addition, although a bayesian framework could have been used at stage 1, we adopted a frequentist framework to leverage available penalization options in existing R packages.…”

The regulatory role and therapeutic application of pyroptosis in musculoskeletal diseases

“…IL-17 production of mucosal-associated invariant cells (MAIT) cells is mediated by IL-7 rather than IL-23 or antigenic stimulation [129]. As to TNF-α, it attributes to microvascular dysfunction and systemic inflammatory reaction [130], and TNF inhibitors could alleviate symptoms and comorbidities [131,132]. Both two pathways could inhibit bone formation, but the connection and hierarchical order between them remains elusive [127].…”